Ketamine Clinical Trials
Investigation of the Rapid (Next Day) Antidepressant Effects of an NMDA Antagonist
To see complete record on clinicaltrials.gov, please visit this link
Id: NCT00088699
Organisation Name: National Institutes of Health Clinical Center (CC)
Overal Status: Completed
Start Date: July 26, 2004
Last Update: October 12, 2018
Lead Sponsor: National Institute of Mental Health (NIMH)
Brief Summary: Depressive disorders may be severe, chronic and often life-threatening illnesses. Impairment in physical and social functioning resulting from depression can be just as severe as other chronic medical illnesses. Recent preclinical and clinical studies suggest that the glutamatergic system is involved in the mechanism of action of antidepressants.
This study examines whether ketamine can cause a rapid-next day antidepressant effect in patients with Major Depressive Disorder.
This study was designed to address the questions:
Does the NMDA antagonist ketamine produce rapid antidepressant effects in patients with treatment-resistant major depression? What are the neurobiological correlates of antidepressant response (examining multi-modal MRI, MEG, polysomnography and serum markers) Patients, ages 18 to 65 years with treatment-resistant major (unipolar) depression will in a double-blind crossover study receive either intravenous ketamine or saline solution.
Conditions:
- Depression
- Mood Disorders
- Major Depresssion
Total execution time in seconds: 0.28795909881592